About Us

Our Mission

  • Improve health outcomes by increasing the quality and availability of difficult-to-procure transfusable blood products
  • Create an emotional connection between donors and our shared mission to save lives
  • Foster an enduring relationship with our hospital customers and provide them an unprecedented level of service quality
  • Serve as a leader in the efforts to modernize and stabilize the blood industry, creating pertinent safeguards in times of supply chain disruption

Our Process

We build

and operate commercial blood collection centers across the US that meet all federal, state, local, AABB, and CLIA standards

We maintain

a pedigreed donor pool through strict adherence to the AABB standards and the use of key predictors of collections efficiencies

We produce

100% pathogen reduced single donor apheresis platelets (PR-SDPs)

We believe

the use of a responsibly compensated donor model is necessary to meet the structurally growing demand for platelets needed for patients

We connect

our donors to the vital role they play in the mission to improve the availability of blood products for patients in their local community

We value

the non-profit blood banking community and the critical role it plays in sustaining the nation’s blood supply

Our Team

Vijai Mohan

Founder and CEO

Vijai is the founder and CEO of Secure Transfusion Services. He spent nearly two decades as a life sciences institutional investor in both private equity and hedge funds, including senior positions at Arcline Investment Management and Origin Capital Management. Previously in his career, he managed corporate finance and investor relations at Onyx Pharmaceuticals, an early gene therapy pioneer. Vijai graduated with a BA in Economics and Molecular Biology, in addition to a Masters in Biotechnology from the University of Pennsylvania.

Vijai is the founder and CEO of Secure Transfusion Services. He spent nearly two decades as a life sciences institutional investor in both private equity and hedge funds, including senior positions at Arcline Investment Management and Origin Capital Management. Previously in his career, he managed corporate finance and investor relations at Onyx Pharmaceuticals, an early gene therapy pioneer. Vijai graduated with a BA in Economics and Molecular Biology, in addition to a Masters in Biotechnology from the University of Pennsylvania.

Kris Jonas

Chief Operating Officer

Kris is a 17-year veteran of Grifols, one of the largest plasma collection companies in the world. During his tenure, Kris held both operational and regulatory leadership positions. Most recently, as  Director of Operations, Kris was directly responsible for 46 plasma centers collecting up to 3 million liters of plasma annually while overseeing more than 2,000 employees. He earned a BS degree from Northwest Nazarene University in 2007 and an MBA from Colorado State University in 2012.

Kris is a 17-year veteran of Grifols, one of the largest plasma collection companies in the world. During his tenure, Kris held both operational and regulatory leadership positions. Most recently, as  Director of Operations, Kris was directly responsible for 46 plasma centers collecting up to 3 million liters of plasma annually while overseeing more than 2,000 employees. He earned a BS degree from Northwest Nazarene University in 2007 and an MBA from Colorado State University in 2012.

Matthew J. Meyer

Chief Business Officer

Matt has over 20 years of executive management, business development, commercial, and legal expertise in private and public life science companies. Matt is also the Chief Client Corporate Development Advisor at Wilson, Sonsini.  Matt was previously Senior Vice President of Corporate Development at Counsyl, which was acquired by Myriad Genetics in 2018, and Chief Business Officer at CareDx, which he helped take public in 2014. Matt has a BA from Cornell University and a JD from Villanova University.

Matt has over 20 years of executive management, business development, commercial, and legal expertise in private and public life science companies. Matt is also the Chief Client Corporate Development Advisor at Wilson, Sonsini.  Matt was previously Senior Vice President of Corporate Development at Counsyl, which was acquired by Myriad Genetics in 2018, and Chief Business Officer at CareDx, which he helped take public in 2014. Matt has a BA from Cornell University and a JD from Villanova University.

Philip Spinella, MD

Chief Science Officer

Phil is the Director of the Pediatric Critical Care Translational Research Program at St Louis Children’s Hospital and Professor of Pediatrics at Washington University School of Medicine. A veteran of the Iraq War, Phil is internationally recognized as an expert in transfusion medicine and the resuscitation of hemorrhagic shock. A co-founder of the THOR Network and its Co-Director since 2011, Phil has published over 200 manuscripts and 16 chapters in the areas of pediatric and adult critical care.

Phil is the Director of the Pediatric Critical Care Translational Research Program at St Louis Children’s Hospital and Professor of Pediatrics at Washington University School of Medicine. A veteran of the Iraq War, Phil is internationally recognized as an expert in transfusion medicine and the resuscitation of hemorrhagic shock. A co-founder of the THOR Network and its Co-Director since 2011, Phil has published over 200 manuscripts and 16 chapters in the areas of pediatric and adult critical care.

Drew Schneider

VP of Business Systems

Drew joined STS with over 10 years of experience at Grifols, where he held roles of increasing responsibility ranging from center director to senior leadership of a business unit.  As Manager of Process and Technology, Drew was responsible for managing business systems, standardizing processes, and introducing new technologies to the Grifols fleet of 200+ plasma collection facilities.  Drew has expertise in all facets of donor center operations and regulatory compliance including, business system integration, process optimization, vendor relations, and new site development.

Drew joined STS with over 10 years of experience at Grifols, where he held roles of increasing responsibility ranging from center director to senior leadership of a business unit.  As Manager of Process and Technology, Drew was responsible for managing business systems, standardizing processes, and introducing new technologies to the Grifols fleet of 200+ plasma collection facilities.  Drew has expertise in all facets of donor center operations and regulatory compliance, including, business system integration, process optimization, vendor relations, and new site development.

Jason Swenson

VP of Regulatory and Quality

Jason has over a decade of experience in quality and regulatory management within the plasma industry. As a regional quality and regulatory affairs manager at Grifols, Jason was responsible for the quality and compliance of over 70,000 annual plasma donations. Jason brings expertise in Food and Drug Administration (FDA) 21 CFR Part 11 compliance, European Medicine Agency (EMA) regulation, Clinical Laboratory Inspection Agency (CLIA) requirements, and Plasma Protein Therapeutic Association (PPTA) guidelines. Jason has a BS in Biology from Bemidji State University.

Jason has over a decade of experience in quality and regulatory management within the plasma industry. As a regional quality and regulatory affairs manager at Grifols, Jason was responsible for the quality and compliance of over 70,000 annual plasma donations. Jason brings expertise in Food and Drug Administration (FDA) 21 CFR Part 11 compliance, European Medicine Agency (EMA) regulation, Clinical Laboratory Inspection Agency (CLIA) requirements, and Plasma Protein Therapeutic Association (PPTA) guidelines. Jason has a BS in Biology from Bemidji State University.

Board of Directors

Laurence Cooper, MD PhDCEO, Ziopharm Oncology, Inc.

Vijai Mohan Founder and CEO, STS

Carol MooreSVP of Regulatory and Quality, Cerus Corporation

George “Bud” Scholl – CEO OneBlood, Inc.

Senior Advisors

Andrew Heaton, MBBS Former Chief Medical Officer, Novartis Diagnostics

Miriam Markowitz – Former CEO, American Association of Blood Banks (AABB)

John Roback, MD PhDDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine

Susan Shurin, MDFormer Deputy Director of National Heart, Lung, and Blood Institute

Our Partners

OneBlood is the third-largest non-profit blood collection organization in the US and is responsible for distributing over one million products annually to 260 hospital partners.
The Cerus INTERCEPT blood system is the only FDA cleared pathogen reduction workflow. INTERCEPT inactivates a range of pathogenic organisms in transfusable blood components. 

Our Affiliations

STS is a member of both the American Association of Blood Banks (AABB) and the Plasma Protein Therapeutics Association (PPTA)